Double Medical(SZ:002901) Sou Hu Cai Jing·2026-01-05 14:28Core Viewpoint - Dabo Medical (002901) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the medical high-value consumables sector [2]. Financial Performance - For the first three quarters of 2025, Dabo Medical reported a main revenue of 1.876 billion yuan, an increase of 22.69% year-on-year [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a 77.03% increase year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 346 million yuan, up 63.99% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 666 million yuan, a 17.82% increase year-on-year [2]. - The single-quarter net profit attributable to shareholders was 180 million yuan, marking a 77.49% increase year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was 123 million yuan, up 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Market Activity - As of January 5, 2026, Dabo Medical's stock closed at 49.63 yuan, up 4.77%, with a turnover rate of 1.07% and a trading volume of 30,900 hands, amounting to a transaction value of 152 million yuan [1]. - On January 5, the net outflow of main funds was 15.42 million yuan, accounting for 10.17% of the total transaction value, while retail investors saw a net inflow of 26.27 million yuan, representing 17.32% of the total transaction value [1].